TGFBR2: A Promising Drug Target and Biomarker for Various Diseases

Target Name: TGFBR2

NCBI ID: G7048

TGFBR2

TGFBR2: A Promising Drug Target and Biomarker for Various Diseases

The transforming growth factor-beta receptor 2 (TGFBR2) is a crucial player in regulating cell growth, differentiation, and homeostasis. It belongs to the superfamily of serine/threonine kinase receptors and is involved in the transforming growth factor-beta (TGF-β) signaling pathway. Dysregulation of TGFBR2 has been linked to numerous diseases, making it an attractive drug target as well as a potential biomarker. In this article, we will explore the significance of TGFBR2 in various diseases and shed light on its potential therapeutic applications.

TGFBR2 and Cancer

Cancer is a complex disease characterized by uncontrolled cell proliferation and the ability to spread to other tissues. The dysregulation of various signaling pathways, including the TGF-β signaling pathway, plays a critical role in cancer progression. TGFBR2 acts as a tumor suppressor in the early stages of cancer by inhibiting cell cycle progression and promoting apoptosis. However, in advanced stages, TGFBR2 can switch its function and promote cancer cell invasion and metastasis. Targeting TGFBR2 may prove to be an effective strategy in inhibiting tumor growth and preventing metastasis.

TGFBR2 and Fibrosis

Fibrosis is a pathological condition characterized by the excessive accumulation of extracellular matrix (ECM) components, leading to tissue scarring and organ dysfunction. TGFBR2 plays a crucial role in the initiation and progression of fibrosis by promoting the production of ECM components and inhibiting their breakdown. Blocking TGFBR2 signaling has shown promising results in experimental models by reducing fibrosis in several organs, including the liver, lung, and kidney. Therapeutic interventions targeting TGFBR2 could potentially alleviate fibrosis-related diseases and improve patient outcomes.

TGFBR2 and Cardiovascular Diseases

Cardiovascular diseases (CVDs), including coronary artery disease, hypertension, and heart failure, are leading causes of morbidity and mortality worldwide. TGFBR2 signaling has been implicated in various aspects of CVD pathogenesis, such as endothelial dysfunction, inflammation, and cardiac remodeling. Disrupting TGFBR2 activation has shown beneficial effects in preclinical models of CVD, attenuating cardiac hypertrophy, fibrosis, and improving contractility. Developing drugs targeting TGFBR2 may offer novel therapeutic options for the prevention and treatment of CVD.

TGFBR2 as a Biomarker

Biomarkers play a key role in disease diagnosis, prognosis, and monitoring treatment response. TGFBR2 has garnered attention as a potential biomarker due to its dysregulation in various disease conditions. Altered TGFBR2 expression levels and mutations have been linked to the prognosis and response to therapy in certain cancers. In addition, TGFBR2 in serum or tissue samples may serve as a diagnostic tool for the early detection of fibrotic diseases or cardiovascular disorders. Further research is needed to establish TGFBR2 as a robust biomarker and develop reliable detection methods.

Targeting TGFBR2: Current Strategies and Future Directions

Several strategies are being explored to target TGFBR2 for therapeutic purposes. Small molecule inhibitors, monoclonal antibodies, and RNA interference-based approaches are among the potential avenues being pursued. For instance, small molecule inhibitors that selectively target the kinase activity of TGFBR2 have shown promising results in preclinical models of cancer and fibrosis. Combination therapies involving TGFBR2 inhibitors with other targeted agents or conventional treatments hold substantial potential. Moreover, identifying predictive biomarkers of response to TGFBR2-targeted therapies is essential for successful implementation.

In conclusion, TGFBR2 holds tremendous promise as both a drug target and biomarker across various diseases. Understanding its multifaceted role in different pathologies will pave the way for the development of precise and effective therapeutic interventions. Developing agents that can selectively modulate TGFBR2 activity while minimizing adverse effects will be crucial for successful clinical translation. The ongoing research in the field of TGFBR2 brings hope for improved patient outcomes and a better understanding of the underlying mechanisms driving diseases.

Protein Name: Transforming Growth Factor Beta Receptor 2

Functions: Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and thus regulates a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways

The "TGFBR2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TGFBR2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets